Review





Similar Products

humanized anti-cd47 monoclonal antibody cd47mab  (Tioma Therapeutics)
90
Tioma Therapeutics humanized anti-cd47 monoclonal antibody cd47mab
Humanized Anti Cd47 Monoclonal Antibody Cd47mab, supplied by Tioma Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/humanized+cd47mab/anti+cd47+antibody/pmc05878706-37-38-43
Average 90 stars, based on 1 article reviews
humanized anti-cd47 monoclonal antibody cd47mab - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
humanized cd47mab  (Tioma Therapeutics)
90
Tioma Therapeutics humanized cd47mab
(A) The <t>CD47mAb</t> was strongly bound to the renal tissue immediately after flushing. (B) CD47mAb binding to glomeruli could be detected on day 5 after transplant. (These staining were performed on grafts from different animals.)
Humanized Cd47mab, supplied by Tioma Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/humanized+cd47mab/anti+cd47+antibody/pmc05878700-140-14-19
Average 90 stars, based on 1 article reviews
humanized cd47mab - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
humanized cd47mab clone anti-cd47 649  (Tioma Therapeutics)
90
Tioma Therapeutics humanized cd47mab clone anti-cd47 649
(A) The <t>CD47mAb</t> was strongly bound to the renal tissue immediately after flushing. (B) CD47mAb binding to glomeruli could be detected on day 5 after transplant. (These staining were performed on grafts from different animals.)
Humanized Cd47mab Clone Anti Cd47 649, supplied by Tioma Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/humanized+cd47mab/anti+cd47+antibody/pmc05878700-65-14-19
Average 90 stars, based on 1 article reviews
humanized cd47mab clone anti-cd47 649 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


(A) The CD47mAb was strongly bound to the renal tissue immediately after flushing. (B) CD47mAb binding to glomeruli could be detected on day 5 after transplant. (These staining were performed on grafts from different animals.)

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) The CD47mAb was strongly bound to the renal tissue immediately after flushing. (B) CD47mAb binding to glomeruli could be detected on day 5 after transplant. (These staining were performed on grafts from different animals.)

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Binding Assay, Staining

Graft blood flow prior (0s) and post reperfusions at 1s, 15s, 30s, and 60s were studied using an in vivo imaging system (n=2/group). (A) Representative perfusion using ICG fluorescence imaging are shown at time points 0, 16 and 60 seconds after release of clamps (see Figure S1 for additional images). (B) The fluorescence density values of the region of interest (ROI) were extracted to evaluate reperfusion characteristics of the grafts. CD47mAb-treated grafts had more uniform and greater average tissue perfusion as compared to control organs. (C) The repeated measure two-way ANOVA shows that Time (p<0.001), Treatment (p=0.002), and Interaction (p<0.001) terms are all significant, indicating florescent density differed by treatment and over time.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: Graft blood flow prior (0s) and post reperfusions at 1s, 15s, 30s, and 60s were studied using an in vivo imaging system (n=2/group). (A) Representative perfusion using ICG fluorescence imaging are shown at time points 0, 16 and 60 seconds after release of clamps (see Figure S1 for additional images). (B) The fluorescence density values of the region of interest (ROI) were extracted to evaluate reperfusion characteristics of the grafts. CD47mAb-treated grafts had more uniform and greater average tissue perfusion as compared to control organs. (C) The repeated measure two-way ANOVA shows that Time (p<0.001), Treatment (p=0.002), and Interaction (p<0.001) terms are all significant, indicating florescent density differed by treatment and over time.

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: In Vivo Imaging, Fluorescence, Imaging

(A) Serum creatinine, blood urea nitrogen (BUN), and phosphorus were significantly decreased, while the calcium levels were significantly increased in the CD47mAb-treated group than that in the control group. (B) Histological study of pig kidney grafts at day 5 post-KTx indicated that CD47mAb treated grafts had significantly less evidence of acute tubular injury (ATI) compared with the control group. (C) Animals with CD47mAb treated grafts had significantly earlier urination than that in control (n=4/group, CD47mAb treatment versus control, *p<0.05 or **p<0.01, respectively).

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Serum creatinine, blood urea nitrogen (BUN), and phosphorus were significantly decreased, while the calcium levels were significantly increased in the CD47mAb-treated group than that in the control group. (B) Histological study of pig kidney grafts at day 5 post-KTx indicated that CD47mAb treated grafts had significantly less evidence of acute tubular injury (ATI) compared with the control group. (C) Animals with CD47mAb treated grafts had significantly earlier urination than that in control (n=4/group, CD47mAb treatment versus control, *p<0.05 or **p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques:

(A) Revealed by qRT-PCR, CD47mAb-treated organs showed significantly less expression in each of these oxidative injury-related genes of superoxide dismutase-1 (sod-1), glutathione peroxidase-1 (gpx-1), thioredoxin (txn), except heme oxygenase-1 (hmox-1) compared to control. (B) Immunofluorescence staining revealed a decreased expression of Voltage-dependent anion-selective channel protein 1 (VDAC-1) and poly (ADP-ribose) polymerase (PARP) in the CD47mAb-treated tissues than in control. (C) Western blotting and (D) densitometry analysis also support that the protein levels of VDAC-1 and PARP are decreased in the grafts treated with CD47mAb compared with control (n=4/group, *p<0.05, ** p<0.01, or *** p<0.001, respectively).

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Revealed by qRT-PCR, CD47mAb-treated organs showed significantly less expression in each of these oxidative injury-related genes of superoxide dismutase-1 (sod-1), glutathione peroxidase-1 (gpx-1), thioredoxin (txn), except heme oxygenase-1 (hmox-1) compared to control. (B) Immunofluorescence staining revealed a decreased expression of Voltage-dependent anion-selective channel protein 1 (VDAC-1) and poly (ADP-ribose) polymerase (PARP) in the CD47mAb-treated tissues than in control. (C) Western blotting and (D) densitometry analysis also support that the protein levels of VDAC-1 and PARP are decreased in the grafts treated with CD47mAb compared with control (n=4/group, *p<0.05, ** p<0.01, or *** p<0.001, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Quantitative RT-PCR, Expressing, Immunofluorescence, Staining, Western Blot

(A) qRT-PCR showed the relative mRNA levels of il-2, il-6, tgf-b, and inf-g were significantly lower in the CD47mAb treated renal allografts than that in control at day 5 after kidney transplantation. (B) Immunofluorescence staining indicated the CD4+ and CD8+ cells infiltration were significantly decreased in the CD47mAb treated renal allografts than that in the control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) qRT-PCR showed the relative mRNA levels of il-2, il-6, tgf-b, and inf-g were significantly lower in the CD47mAb treated renal allografts than that in control at day 5 after kidney transplantation. (B) Immunofluorescence staining indicated the CD4+ and CD8+ cells infiltration were significantly decreased in the CD47mAb treated renal allografts than that in the control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Quantitative RT-PCR, Transplantation Assay, Immunofluorescence, Staining

(A) Immunofluorescence staining showed a reduction of matrix metalloproteinase-2 (MMP-2) and MMP-9 in CD47mAb treated renal allografts than that in control. Western blotting (B) and densitometry analysis (C) confirmed the decreasing expression of MMP-2 and MMP-9 in renal grafts treated with CD47mAb compared to control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Immunofluorescence staining showed a reduction of matrix metalloproteinase-2 (MMP-2) and MMP-9 in CD47mAb treated renal allografts than that in control. Western blotting (B) and densitometry analysis (C) confirmed the decreasing expression of MMP-2 and MMP-9 in renal grafts treated with CD47mAb compared to control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Immunofluorescence, Staining, Western Blot, Expressing

(A) Immunofluorescence staining showed a decrease of Bcl-2-associated X protein (BAX) and Caspase-3 in the CD47mAb treated renal allografts compared to control. Western blotting (B) and densitometry analysis (C) confirmed the decreasing expression of BAX and Caspase-3 in renal grafts treated with CD47mAb than that in control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Immunofluorescence staining showed a decrease of Bcl-2-associated X protein (BAX) and Caspase-3 in the CD47mAb treated renal allografts compared to control. Western blotting (B) and densitometry analysis (C) confirmed the decreasing expression of BAX and Caspase-3 in renal grafts treated with CD47mAb than that in control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Immunofluorescence, Staining, Western Blot, Expressing

(A) The CD47mAb was strongly bound to the renal tissue immediately after flushing. (B) CD47mAb binding to glomeruli could be detected on day 5 after transplant. (These staining were performed on grafts from different animals.)

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) The CD47mAb was strongly bound to the renal tissue immediately after flushing. (B) CD47mAb binding to glomeruli could be detected on day 5 after transplant. (These staining were performed on grafts from different animals.)

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Binding Assay, Staining

Graft blood flow prior (0s) and post reperfusions at 1s, 15s, 30s, and 60s were studied using an in vivo imaging system (n=2/group). (A) Representative perfusion using ICG fluorescence imaging are shown at time points 0, 16 and 60 seconds after release of clamps (see Figure S1 for additional images). (B) The fluorescence density values of the region of interest (ROI) were extracted to evaluate reperfusion characteristics of the grafts. CD47mAb-treated grafts had more uniform and greater average tissue perfusion as compared to control organs. (C) The repeated measure two-way ANOVA shows that Time (p<0.001), Treatment (p=0.002), and Interaction (p<0.001) terms are all significant, indicating florescent density differed by treatment and over time.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: Graft blood flow prior (0s) and post reperfusions at 1s, 15s, 30s, and 60s were studied using an in vivo imaging system (n=2/group). (A) Representative perfusion using ICG fluorescence imaging are shown at time points 0, 16 and 60 seconds after release of clamps (see Figure S1 for additional images). (B) The fluorescence density values of the region of interest (ROI) were extracted to evaluate reperfusion characteristics of the grafts. CD47mAb-treated grafts had more uniform and greater average tissue perfusion as compared to control organs. (C) The repeated measure two-way ANOVA shows that Time (p<0.001), Treatment (p=0.002), and Interaction (p<0.001) terms are all significant, indicating florescent density differed by treatment and over time.

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: In Vivo Imaging, Fluorescence, Imaging, Control

(A) Serum creatinine, blood urea nitrogen (BUN), and phosphorus were significantly decreased, while the calcium levels were significantly increased in the CD47mAb-treated group than that in the control group. (B) Histological study of pig kidney grafts at day 5 post-KTx indicated that CD47mAb treated grafts had significantly less evidence of acute tubular injury (ATI) compared with the control group. (C) Animals with CD47mAb treated grafts had significantly earlier urination than that in control (n=4/group, CD47mAb treatment versus control, *p<0.05 or **p<0.01, respectively).

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Serum creatinine, blood urea nitrogen (BUN), and phosphorus were significantly decreased, while the calcium levels were significantly increased in the CD47mAb-treated group than that in the control group. (B) Histological study of pig kidney grafts at day 5 post-KTx indicated that CD47mAb treated grafts had significantly less evidence of acute tubular injury (ATI) compared with the control group. (C) Animals with CD47mAb treated grafts had significantly earlier urination than that in control (n=4/group, CD47mAb treatment versus control, *p<0.05 or **p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Control

(A) Revealed by qRT-PCR, CD47mAb-treated organs showed significantly less expression in each of these oxidative injury-related genes of superoxide dismutase-1 (sod-1), glutathione peroxidase-1 (gpx-1), thioredoxin (txn), except heme oxygenase-1 (hmox-1) compared to control. (B) Immunofluorescence staining revealed a decreased expression of Voltage-dependent anion-selective channel protein 1 (VDAC-1) and poly (ADP-ribose) polymerase (PARP) in the CD47mAb-treated tissues than in control. (C) Western blotting and (D) densitometry analysis also support that the protein levels of VDAC-1 and PARP are decreased in the grafts treated with CD47mAb compared with control (n=4/group, *p<0.05, ** p<0.01, or *** p<0.001, respectively).

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Revealed by qRT-PCR, CD47mAb-treated organs showed significantly less expression in each of these oxidative injury-related genes of superoxide dismutase-1 (sod-1), glutathione peroxidase-1 (gpx-1), thioredoxin (txn), except heme oxygenase-1 (hmox-1) compared to control. (B) Immunofluorescence staining revealed a decreased expression of Voltage-dependent anion-selective channel protein 1 (VDAC-1) and poly (ADP-ribose) polymerase (PARP) in the CD47mAb-treated tissues than in control. (C) Western blotting and (D) densitometry analysis also support that the protein levels of VDAC-1 and PARP are decreased in the grafts treated with CD47mAb compared with control (n=4/group, *p<0.05, ** p<0.01, or *** p<0.001, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Quantitative RT-PCR, Expressing, Control, Immunofluorescence, Staining, Western Blot

(A) qRT-PCR showed the relative mRNA levels of il-2, il-6, tgf-b, and inf-g were significantly lower in the CD47mAb treated renal allografts than that in control at day 5 after kidney transplantation. (B) Immunofluorescence staining indicated the CD4+ and CD8+ cells infiltration were significantly decreased in the CD47mAb treated renal allografts than that in the control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) qRT-PCR showed the relative mRNA levels of il-2, il-6, tgf-b, and inf-g were significantly lower in the CD47mAb treated renal allografts than that in control at day 5 after kidney transplantation. (B) Immunofluorescence staining indicated the CD4+ and CD8+ cells infiltration were significantly decreased in the CD47mAb treated renal allografts than that in the control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Quantitative RT-PCR, Control, Transplantation Assay, Immunofluorescence, Staining

(A) Immunofluorescence staining showed a reduction of matrix metalloproteinase-2 (MMP-2) and MMP-9 in CD47mAb treated renal allografts than that in control. Western blotting (B) and densitometry analysis (C) confirmed the decreasing expression of MMP-2 and MMP-9 in renal grafts treated with CD47mAb compared to control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Immunofluorescence staining showed a reduction of matrix metalloproteinase-2 (MMP-2) and MMP-9 in CD47mAb treated renal allografts than that in control. Western blotting (B) and densitometry analysis (C) confirmed the decreasing expression of MMP-2 and MMP-9 in renal grafts treated with CD47mAb compared to control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Immunofluorescence, Staining, Control, Western Blot, Expressing

(A) Immunofluorescence staining showed a decrease of Bcl-2-associated X protein (BAX) and Caspase-3 in the CD47mAb treated renal allografts compared to control. Western blotting (B) and densitometry analysis (C) confirmed the decreasing expression of BAX and Caspase-3 in renal grafts treated with CD47mAb than that in control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Article Title: Anti-CD47 Monoclonal Antibody Therapy Reduces Ischemia-Reperfusion Injury of Renal Allografts in a Porcine Model of Donation after Cardiac Death

doi: 10.1111/ajt.14567

Figure Lengend Snippet: (A) Immunofluorescence staining showed a decrease of Bcl-2-associated X protein (BAX) and Caspase-3 in the CD47mAb treated renal allografts compared to control. Western blotting (B) and densitometry analysis (C) confirmed the decreasing expression of BAX and Caspase-3 in renal grafts treated with CD47mAb than that in control (n=4/group, *p<0.05 or ** p<0.01, respectively).

Article Snippet: Just prior to implantation, the grafts were flushed either with control (n=4) or a humanized CD47mAb (clone anti-CD47 649, Tioma Therapeutics, Inc, St. Louis, n=4) at a dosage of 10 mg per 250–300 g kidney.

Techniques: Immunofluorescence, Staining, Control, Western Blot, Expressing